Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 28;27(24):3609–3629. doi: 10.3748/wjg.v27.i24.3609

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

PMC Copyright notice

Analysis of difference in fecal bile acids between the ulcerative colitis and control groups. A: Principal component analysis was performed to evaluate the similarity of the fecal BAs of the two groups. Twenty-four BAs clearly distinguished the ulcerative colitis (UC) group from the control group; B: Heatmap showing the individual BA concentrations in the samples (log-transformed). Shades of red and blue represent high and low BA concentrations, respectively (see color scale); C-H: Fecal secondary BAs in UC patients, such as lithocholic acid, deoxycholic acid, glyco-deoxycholic acid, glyco-lithocholic acid, and tauro-lithocholate, were significantly lower than those in healthy controls; I and K-M: The primary BAs such as tauro-cholic acid, cholic acid, tauro-chenodeoxycholic acid, and glyco-chenodeoxycholic acid were significantly higher than those in healthy controls; J and N: The concentrations of chenodeoxycholic acid and glyco-cholic acid showed a tendency to increase in UC patients but the increases were not significant. UC: Ulcerative colitis; PCA: Principal component analysis; BAs: Bile acids; LCA: Lithocholic acid; DCA: Deoxycholic acid; GDCA: Glyco-deoxycholic acid; GLCA: Glyco-lithocholic acid; TLCA: Tauro-lithocholate; TCA: Tauro-cholic acid; CA: Cholic acid; TCDCA: Tauro-chenodeoxycholic acid; GCDCA: Glyco-chenodeoxycholic acid; CDCA: Chenodeoxycholic acid; GCA: Glyco-cholic acid.